CrossRef G2E3 Suppresses the TumorKilling Function of CD8+ T Cells in Hepatocellular Carcinoma by Boosting CLCN2 Ubiquitination Fan Zhou, Ting Chen, Xingguo Tan, Jun Yu, Mengzhi Xiao, Jun Guo The FASEB Journal .2026;[Epub] CrossRef Tumor burden score determines survival benefit of anatomic resection in hepatocellular carcinoma: A multicenter propensity-matched study Shujie Pang, Yang Shi, Minjun Jiang, Qingwang Ye, Xin Yan, Zhe Sun, Xingrui Kou, Xiaoxiang Chen, Hui SiMa, Yiming Chen, Yingcheng Yang, Ning Yang European Journal of Surgical Oncology .2026
National Institutes of Health Obes Res
Dee Jittla 8 June 2026 3 min read The Peptide Problem: Hype Outpaces Evidence for Popular Injectables Explore the growing trend of injectable peptides like TB-500, the significant gap between their purported benefits and scientific evidence, and the serious safety concerns raised by regulatory bodies
Benefits consultants who identify a $500-per-employee-per-year savings opportunity from switching generic drug procurement to a Cost Plus-affiliated model have strong financial incentives to recommend that switch to their clients
Four samples with declared mesterolone were tested
